Loss of E-cadherin (CDH1) expression with the gain in N-cadherin and vimentin (VIM) expression associated with mesenchymal phenotype (enhanced migration, secretion of extracellular matrix [ECM] degrading proteases and ECM remodeling etc.)have been clinically associated with poor prognosis in many cancers [3, 6–8]. Here, CDH1 is linked to cancer.